Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:203. https://doi.org/10.3322/caac.21820

Article  Google Scholar 

Liu B, Zhou H, Tan L, Siu KTH, Guan X-Y (2024) Exploring treatment options in cancer : tumor treatment strategies. Signal Transduct Target Ther 9:175. https://doi.org/10.3322/caac.21820

Article  PubMed  PubMed Central  Google Scholar 

Choi HY, Chang J (2023) Targeted therapy for cancers : from ongoing clinical trials to FDA approved drugs. Int J Mol Sci 24:13618. https://doi.org/10.3390/ijms241713618

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faber J et al (2006) HoxA9 knockdown inhibits proliferation and induces cell death in human MLL-rearranged leukemias. Blood 108:734. https://doi.org/10.1182/blood.V108.11.734.734

Article  Google Scholar 

Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823–833. https://doi.org/10.1038/nrc2253

Article  CAS  PubMed  Google Scholar 

Imamura T, Morimoto A, Takanashi M, Hibi S, Sugimoto T (2002) Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol 119:119–121. https://doi.org/10.1046/j.1365-2141.2002.03803.x

Article  CAS  PubMed  Google Scholar 

Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE (1999) Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13:687–698. https://doi.org/10.1038/sj.leu.2401410

Article  CAS  PubMed  Google Scholar 

Golub TR et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–527. https://doi.org/10.1126/science.286.5439.531

Article  CAS  PubMed  Google Scholar 

Gao L, Sun J, Liu F, Zhang H, Ma Y (2016)) Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia. Onco Targets Ther 9:711–722. https://doi.org/10.2147/OTT.S95279

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andreeff M et al (2008) HOX expression patterns identify a common signature for favorable AML. Leukemia 22:2041–2047. https://doi.org/10.1038/leu.2008.198

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambert M et al (2019) Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia. Cancers (Basel) 17:837–875. https://doi.org/10.3390/cancers11060837

Article  CAS  Google Scholar 

Aryal S, Zhang Y, Wren S, Li C, Lu R (2021) Molecular regulators of HOXA9 in acute myeloid leukemia. FEBS J 2:3–9. https://doi.org/10.1111/febs.16268

Article  CAS  Google Scholar 

Collins CT, Hess JL (2016) Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Physiol Behav 176:139–148. https://doi.org/10.1038/onc.2015.174

Article  CAS  Google Scholar 

Cao Q et al (2016) BCOR regulates myeloid cell proliferation and differentiation Qi. Leukemia 30:1155–1165. https://doi.org/10.1038/leu.2016.2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunetti L, Gundry MC, Goodell MA (2017) DNMT3A in leukemia. Cold Spring Harb Perspect Med 7:a030320. https://doi.org/10.1101/cshperspect.a030320

Article  PubMed  PubMed Central  Google Scholar 

Balgobind BV, Zwaan CM, Pieters R, Van Den Heuvel-Eibrink MM (2011) The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 25:1239–1248. https://doi.org/10.1038/leu.2011.90

Article  CAS  PubMed  Google Scholar 

Zhang W, Gou P, Dupret J-M, Chomienne C, Rodrigues-Lima F (2021) Etoposide, an anticancer drug involved in therapy-related secondary leukemia: enzymes at play. Transl Oncol 14:101169. https://doi.org/10.1016/j.tranon.2021.101169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi A et al (2012) Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120:4461–4469. https://doi.org/10.1182/blood-2012-05-429274

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown P (2013) Treatment of infant leukemias: challenge and promise. Am Soc Hematol 1:596–600. https://doi.org/10.1182/asheducation-2013.1.596

Article  Google Scholar 

Meyer C et al (2023) The KMT2A recombinome of acute leukemias in 2023. Leukemia 37:988–1005. https://doi.org/10.1038/s41375-023-01877-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyer C et al (2018) The MLL recombinome of acute leukemias in 2017. Leukemia 32:273–284. https://doi.org/10.1038/leu.2017.213

Article  CAS  PubMed  Google Scholar 

Meyer C et al (2009) New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490–1499. https://doi.org/10.1038/leu.2009.33

Article  CAS  PubMed  Google Scholar 

Stubbins RJ, Francis A, Kuchenbauer F, Sanford D (2022) Management of acute myeloid leukemia: a review for general practitioners in oncology. Curr Oncol 29:6245–6259. https://doi.org/10.3390/curroncol29090491

Article  PubMed  PubMed Central  Google Scholar 

Orlovsky K et al (2011) Down-regulation of homeobox genes MEIS1 and HOXA in MLL -rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci U S A 108:7956–7961. https://doi.org/10.1073/pnas.1103154108

Article  PubMed  PubMed Central  Google Scholar 

Faber J et al (2009) HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113:2375–2385. https://doi.org/10.1182/blood-2007-09-113597

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lambert M et al (2024) Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9-dependent AML. HemaSphere 6:e77. https://doi.org/10.1002/hem3.77

Article  CAS  Google Scholar 

Sun Y et al (2018) HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell 34:643-658.e5. https://doi.org/10.1016/j.ccell.2018.08.018

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daigle SR et al (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122:1017–1025. https://doi.org/10.1182/blood-2013-04-497644

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daigle SR et al (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53–65. https://doi.org/10.1016/j.ccr.2011.06.009

Article  CAS  PubMed  PubMed Central